

Haematologica
HAEMATOL/2018/198820
Version 3

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort

Maria Winqvist, Per-Ola Andersson, Anna Asklid, Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Richard Rosenquist, Florentin Späth, Lotta Hansson, and Anders Österborg

Disclosures: AÖ has received research grant support and honoraria for scientific lectures from Janssen. LH has received research grant support from Janssen. POA has received consulting honoraria from Janssen.

Contributions: MW, LH and AÖ designed the study, analyzed the data and performed the statistical analysis. All authors but RR treated patients. RR was responsible for the BTK mutation tests. All authors wrote and approved the manuscript.